Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of KHK2375 (entinostat) plus exemestane in advanced or recurrent breast cancer
jRCT2080223012Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of entinostat in breast cancer, sponsored by Kyowa Kirin. Primary endpoint: Dose-limiting toxicity (DLT) and tolerability of entinostat. Started Nov 2015; status: completed.
02
Drugs
entinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223012.